Form 8-K - Current report

true0001541157false00015411572025-01-132025-01-130001541157dei:AdrMember2025-01-132025-01-130001541157aktx:OrdinarySharesParValue0.0001PerShareMember2025-01-132025-01-13

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 13, 2025

 

Akari Therapeutics, Plc

(Exact Name of Registrant as Specified in Charter)

England and Wales		001-36288		98-1034922
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

22 Boston Wharf Road FL 7

Boston, MA 02210

(Address, including zip code, of Principal Executive Offices)

Registrant’s telephone number, including area code: [phone]

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing 2,000 Ordinary Shares		AKTX		The Nasdaq Capital Market
Ordinary Shares, par value $0.0001 per share*

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

---

 

Item 7.01 Regulation FD Disclosure.

 

On January 13, 2025, Akari Therapeutics, Plc (the “Company”) updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings from time to time.

 

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.		Description
99.1		Corporate Presentation
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

 

---

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Akari Therapeutics, Plc
Date: January 13, 2025	By:	/s/ Samir R. Patel, M.D.
		Samir R. Patel, M.D.
		President and Chief Executive Officer

​

 

---

Corporate Presentation January 2025 NASDAQ: AKTX akaritx.com Next-Generation Precision Bi-Functional Antibody Drug Conjugates

---

Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc (the “Company”) that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the business combination and related matters, including, but not limited to, post-closing operations and the outlook for the Company’s business; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates; financial projections; future economic performance; and the assumptions underlying or relating to such statements. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the risk that the Company may not realize the anticipated benefits of its merger with Peak Bio, Inc. (the “Merger”) in the time frame expected, or at all; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the Merger; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business; uncertainties as to the long-term value of the Company’s American Depositary Shares (“ADSs”) (and the ordinary shares represented thereby), including the dilution caused by the Company’s issuance of additional ADSs (and the ordinary shares represented thereby) in connection with the Merger; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; unexpected breaches or terminations with respect to the Company’s material contracts or arrangements; risks related to competition for the Company’s product candidates; the Company’s ability to successfully develop or commercialize its product candidates; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of the Company’s product candidates; the Company’s ability to maintain listing of its ADSs on the Nasdaq Capital Market. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

---

WE ARE Akari Therapeutics is an innovative targeted oncology company built on next-generation ADCs and a novel discovery engine AKARI THERAPEUTICS

---

Innovative Precision Antibody Drug Conjugates (ADCs) for the Treatment of Cancer Why Akari Discovery platform allows for generation of novel Bi-Functional ADC candidates with spliceosome inhibitor payload Significant advantages over current TROP2 ADCs observed in multiple preclinical models: Superior activity Prolonged survival Less resistance Better tolerability Prolonged survival in combination with checkpoint inhibitors (CPI) Lead Candidate AKTX-101 (TROP2 PH1 ADC) Capital Efficient with Multiple Near-Term Milestones Lean team focused on Execution Opportunity for Non-Dilutive Capital Through Partnering of Legacy Pipeline BD Discussions ongoing with interested licensing/strategic partners Tunable Target, Linker and Payload

---

Global ADC Market Expected to Grow Significantly1 Antibody drug conjugates market. Market.us. (2023, November 3). https://market.us/report/antibody-drug-conjugates-market/ 2023 Sales from Approved ADCs ADCs Have Revolutionized Cancer Therapy, But Have Some Shortcomings Solid Tumors Liquid Tumors Product Toxin Class 2023 Sales DNA Damaging Agent $1.0B DNA Damaging Agent $2.7B Microtubule Inhibitor <$100M Microtubule Inhibitor $1.75B Microtubule Inhibitor $1.3B Microtubule Inhibitor $150M Microtubule Inhibitor $750M Microtubule Inhibitor $1.5B DNA Damaging Agent <$100M DNA Damaging Agent $140M DNA Damaging Agent <$100M All Currently Approved ADCs Utilize Only One of Two Payload Toxin Classes, Which Are Known for Toxicity and Resistance Issues Limited Combination Ability with Other Key Therapies Like Anti-PD1/Anti-PDL1 Tubulin Inhibitors | DNA Damaging Agents

---

Bi-Functional ADC Platform Targeting Cancer Antibody Targeting Clinically Validated TROP2 Receptor on Tumor Cells Linker Connects Anti-Tumor Payload to Targeting Antibody Payload Differentiated Novel PH1 Payload Disrupts Normal RNA Splicing, Leading to Cancer Cell Apoptosis Highly Selective Cancer Cell Death Combined With Enhanced Immune System Engagement for Effective Tumor Eradication Potential to Overcome Shortcomings of Current ADCs Low Off-Target Toxicity Enhanced Activityas a Single Agent Potential to Overcome Tumor Resistance Mechanisms Ability to Induce Epitope Spreading

---

Next-Generation Precision ADC Pipeline Program Indication Discovery Preclinical Clinical Highlights AKTX-101 (TROP2 PH1 ADC) ADC with Novel Payload Solid Tumors Novel Payload: PH1 Advancing IND-enabling preclinical studies Pursue licensing / strategic partnership AKTX-102 (Undisclosed Target) ADC with Novel Payload Undisclosed Novel Payload: PH5 Payload targeting DNA Mismatch Repair (MMR) to generate neoepitopes AKTX-103 (Undisclosed Target) ADC with Novel Payload Undisclosed Novel Payload: PH6Payload targeting DNA transcription in cancer cells and co-opted immune cells Platform Technology to Fuel Pipeline with Ability to Generate Novel ADC Candidates Across a Range of Solid/Hematological Cancers

---

Application Targeting Antibody Proprietary Linkers Anti-Cancer Payload Lung Cancer CD20 Lys-L92 Colorectal Cancer Nectin-4 Lys-L91 Prostate Cancer HER2 LYS-L2 PH5 Breast Cancer TROP2 LYS-L22 PH1 Stomach Cancer HER3 Cys-L18 PH6 Pancreatic Cancer DLL3 Cys-L11 Ovarian Cancer ROR1 Cys-L94 Liver Cancer Akari Platform Technology Can Fuel a Pipeline Ability to Precisely Tune Assets for Purpose Allows for Multiple Program Development for Additional Licensing Partnerships Program AKTX-101 Ability to generate novel ADC candidates against any relevant target across a range of cancers Proprietary to Akari

---

Novel PH1 Payload: Superior Activity With Potent Effect Across Various Tumors Types and Targets Using Platform Technology Her2 Gastric Her2High Breast Her2Low Trop2 Gastric TropHigh Bladder Trop2Heterogenous NSCLC TargetMedium Pancreatic Trop2High In Vitro Studies Performed at Lower PH1 Drug Dose (Lower DAR) Undisclosed These data are derived from comparative non-clinical studies and are not intended to serve as a basis for comparison with respect to Trodelvy's or any other clinical studies.

---

AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity Reduced Off-Target Toxicity Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity Overcomes Resistance Mechanisms Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy Potential for Synergy With Immunotherapies Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies Potential to Overcome Shortcomings of Current ADCs

---

Antibody receptor complex is internalized by endocytosis. PH1 ADC binds to the target receptor. 1 Lysosome fuses with endosome. Lysosomal enzymes degrade the ADC, releasing the active payload species. PH1 disrupts alternative splicing in the tumor cell, a fundamental process for tumor transformation and growth. Active payload Resulting mRNA decay deprives cancer cells of essential proteins. Accumulation of mis-spliced proteins induce cell death by unfolded protein response (UPR) and endoplasmic reticulum stress. Neoantigen MHC Ribosome mRNA Spliceosome PH1 TROP2 Bi-functional results of PH1 targeted splicing Endosome TUMOR CELL MEMBRANE NUCLEUS Payload cytotoxicity and TGI in xenograft models Neoantigen formation can stimulate the immune response and induce tumor growth inhibition (TGI) in syngeneic model. SF3B1 SF3B2 PH5a Pre-mRNA 2 3 4 AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of NeoantigensBi-Functional Payload Targeting the Spliceosome

---

Active payload kills majority of target cells Stimulates payload-induced neoepitopes in survivors Resistant cells killed by immune response TARGET CELL T cells recognize neoantigens and become primed for killing tumor cells Synergy with checkpoint inhibitor therapies that further enhance immune response Antibody response Activation B cells recognize neoantigens and become primed for killing tumor cells Activation Myeloid cell T cell B cell Myeloid cells phagocytose and release granules Target receptor (Her2 or Trop2) PH1 ADC Payload induced neoepitope Cancer neoepitope TCR Immune response targets surrounding cancer cells without a chemical bystander effect TARGETNONE EXPRESSING CELLS Some cell death directly from lower payload concentrations Some payload-induced neoepitopes Immune cell mediated death TARGETLOW EXPRESSING CELLS HIGHLY IMMUNOGENIC CELL MODERATELY IMMUNOGENIC CELL WEAKLY IMMUNOGENIC CELL Checkpoint inhibitor AKTX-101: Immune Response to Payload-Induced Neoantigens Extends Beyond ADC Target Receptor

---

PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge with Tumor Cells Potent Synergy With Checkpoint Inhibitor Has Potential to Cure Colorectal Tumors PH1 Induced Tumor-Specific Immune Memory Tumor-regressed MC38-hHer2 ADC Doses Rechallenge MC38-hHer2 B16-F10 ADC Treatment and Survival Curves Rechallenge Tumor Grows on Right Hand Side of mouse No Tumor on Left Hand Side of Mouse B16-F10 Challenge MC38-hHer2 Challenge

---

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity Overcomes Resistance Mechanisms Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy Potential to Overcome Shortcomings of Current ADCs Reduced Off-Target Toxicity Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity Potential for Synergy With Immunotherapies Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

---

AKTX-101:Demonstrated ReducedOff-Target Toxicity in Preclinical Study Normal Human Fibroblasts TROP2none Limited effect on Normal Human Fibroblasts, an example of off-target toxicity of Trodelvy® No cytotoxicity against normal human fibroblasts as observed in FIC(Attributed to superior linker stability) Proprietary Linker Only Releases PH1 Payload Upon Cell Internalization – No Leakage Suggests Potential for Higher Therapeutic Index These data are derived from comparative non-clinical studies and are not intended to serve as a basis for comparison with respect to Trodelvy's or any other clinical studies.

---

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity Overcomes Resistance Mechanisms Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy Potential to Overcome Shortcomings of Current ADCs Reduced Off-Target Toxicity Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity Potential for Synergy With Immunotherapies Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

---

AKTX-101: Shown to Avoid Development of Resistance in Preclinical Study PH1 potency unaffected by overexpression of multidrug resistance (MDR) transporters 200X higher MMAE concentration required to kill cells overexpressing MDRs; inhibition of MDR 1/2 by elacridar restores MMAE potency PH1 Payload is Designed to Evade MDR Transporter Efflux Pumps and is unaffected by mutations in Tubulin or DNA Damage Pathways that confer resistance to microtubule and topoisomerase inhibitor payloads Method: Normal MES-SA cells & MES-SA cells selected for overexpression of MDR transporter 1/2 exposed in vitro to PH1 or anti-tubulin payload MMAE (monomethyl auristatin E), in presence or absence of MDR 1/2 inhibitor elacridar MES-SA uterine sarcoma cell line MES-SA cells expressing high levels of MDR transporter 1 and 2 which can pump toxins out of cells MES-SA cells with high MDR expression + MDR inhibitor elacridar Patients who develop resistance to current TROP2 ADCs, may still be candidates for AKTX-101 due to differentiated PH1 payload mechanism

---

Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Immunostimulatory Effects Accumulation of mis-spliced proteins generates neoantigens that can be recognized by the immune system, potentially enhancing anti-tumor immunity Overcomes Resistance Mechanisms Appears to be a poor substrate for MDR transporters, which are often responsible for drug resistance in cancer therapy Potential to Overcome Shortcomings of Current ADCs Reduced Off-Target Toxicity Proprietary linker and tumor selective antibodies that spare normal cells potentially reducing off-target toxicity Potential for Synergy With Immunotherapies Immunomodulatory properties may synergize with checkpoint inhibitors and other immunotherapies AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms

---

AKTX-101 Demonstrated Anti-Tumor Activity and Improved Overall Survival in Combination With Standard of Care I/O Note: Patent pending so exact model, I/O drug and dosing not disclosed Superior Overall Survival Combination With IO Superior Anti-Tumor Efficacy In Combination With IO Mouse Bladder Syngeneic Cancer Tumor Model (Urothelial) Expressing Human TROP2 Protein Comparable to SOC and Superior in Combination With I/O Benefit in OS Compared to SOC and Superior in Combination With I/O

---

Licensee Licensor Phase Asset Target Date Deal Type Upfront Payment Total Deal Highlights Preclinical ADC Technologies Undisclosed 1/2025 Licensing Undisclosed Undisclosed upfront payment and up to $1.3 billion, plus additional royalty payments on net sales of resulting products Preclinical AVZO-1418/DB-1418 EGFR/HER3 1/2025 Licensing $50M $50 million and will be eligible to receive up to approximately $1.15 billion in development, regulatory and commercial milestone payments Preclinical 3 ADCs PTK7-ADC, MUC16-ADC, SEZ6-ADC 12/2024 Licensing $44M $44M upfront + $265M in development and $540M in commercial milestones, plus single-digit royalty (all 3 assets included) Preclinical EO-1022 HER3 12/2024 Licensing $368M $368 million in upfront and clinical, regulatory, and commercial milestone payments, plus tiered royalties on net sales Preclinical DB-1324 Undisclosed 12/2024 Licensing $30M $30M upfront, plus pre-option milestones and up to $975M in milestones and tiered royalties on sales Preclinical Alco5 Tech Undisclosed 12/2024 Licensing $20M $20M upfront, plus potential for $30M option and up to $415M in milestones and low double-digit royalties Preclinical VAC-103 Nectin4/ TROP2 11/2024 Option $50M $50 million and potential development, regulatory, and commercial milestone payments of up to approximately $750 million in total, as well as tiered royalties on sales Preclinical SKB571 Undisclosed 9/2024 Licensing $35M $35m upfront, $37.5m on option exercise, undisclosed sales milestones and tiered royalties Preclinical TMALIN ADC platform Undisclosed 6/2024 Licensing $25M $25M upfront; Up to $1.8B in milestones Preclinical Targets Undisclosed 4/2024 Licensing NA Up to $1.4B in milestones Preclinical STRO-003 ROR1 4/2024 Licensing $90M $90M upfront; Phase 1 by Ipsen $900M in milestones Preclinical LM-305 GPRC5D 4/2023 Licensing $55M $55M upfront; $545M milestones Preclinical Tubutecan payloads and p5 conjugation platform Undisclosed 4/2023 Collaboration $22M $22.75M upfront; $1B milestones Preclinical Undisclosed Undisclosed 7/2022 Licensing $35M $35M upfront; $901M milestones Preclinical Camptothecins Undisclosed 2/2022 Licensing $13M+$32.5M $13M+$32.5M upfront; $1.7B milestones Significant Big Pharma Interest and Deal Flow in Early-Stage ADCs 20

---

Proven Management Team Samir R. Patel, MD Chief Executive Officer Serial entrepreneur with more than 20 years of experience in life sciences with multiple successful exits Torsten Hombeck, PhD Chief Financial Officer Seasoned executive with over 20 years of expertise in finance, capital markets and M&A Miles Nunn, D. PhilChief Scientific Officer Accomplished scientist and drug developer with over two decades of experience, including the discovery of nomacopan Satyajit Mitra, PhDExecutive Director, Head of Oncology Scientist with 20 years in advancing novel oncology programs from early preclinical validation and lead selection through pipeline nomination

---

Highly Experienced, Involved, Knowledgeable Board to Help Steer Strategy and Execution Hoyoung Huh, MD, PhD Chairman Founder of Peak Bio Inc. and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015 Samir R. Patel, MD Chief Executive Officer CEO since December of 2024, founder and principal of PranaBio Investments, has more than 20 years of experience in life sciences including co-founding Digital Therapeutics, LLC Ray Prudo, MD Director Founder, Chairman, and CEO of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, and is currently a board member of several UK healthcare companies James Neal, MS, MBA Director More than 25 years’ experience in forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market Sandip I. Patel JD, BBA Director Involved in the formation, development, growth, and successful exits of several companies in the healthcare services and technology sector, insurance, and financial services Robert Bazemore Director Seasoned executive leader, board member and innovator with over 35 years experience in portfolio strategy, partnering, development and commercialization of novel therapeutics, predominantly in Oncology and Immunology Abizer Gaslightwala Director 25 years in the development and commercialization of novel medicines with extensive experience in Oncology; developed, launched, and driven growth of several oncology products and brands spanning cancers with a focus on targeted agents including HER2, VEGF, CD20, and EGFR

---

Upcoming Expected Value Driving Milestones Building a Next-Generation Precision Bi-Functional ADC Platform Legacy Pipeline Assets Present anticipated PH1 Payload Preclinical Data at Scientific Conference Complete additional IND-enabling preclinical studies for AKTX-101 Generate additional validating data on novel payloads to support pipeline Round out Executive Team with critical hires Seeking licensing/strategic partner for AKTX-101 (TROP2 PH1 ADC) BD Efforts To Secure Development Partners And Provide Non-Dilutive Capital Ongoing and Near-Term Ongoing

---

Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Global Market Opportunity PAS-Nomacopan Long-Acting Complement C5 & Leukotriene B4 Inhibitor for Eye Geographic Atrophy $23 Billion1 PHP-303 Neutrophil Elastase Inhibitor Alpha-1 Antitrypsin Deficiency $1.4 Billion2 Acute Respiratory Distress Syndrome $3.4 Billion3 Nomacopan Complement C5 & Leukotriene B4 Inhibitor for Systemic Conditions Bullous Pemphigoid; Paroxysmal Nocturnal Hemoglobinuria >$5 Billion4 Trauma $15 Billion5 Assets Beyond ADC Platform Opportunity for Non-Dilutive Capital Through Ongoing BD Activities to Secure Development Partner for Inactive Programs Geographic atrophy (GA) market size, Share report, 2024-2032. Geographic Atrophy (GA) Market Size, Share Report, 2024-2032. (n.d.). https://www.snsinsider.com/reports/geographic-atrophy-ga-market-2480 Alpha-1 antitrypsin deficiency market size & forecast - 2034. Size & Forecast - 2034. (n.d.). https://www.imarcgroup.com/alpha-1-antitrypsin-deficiency-market Global acute respiratory distress syndrome (ARDS) treatment market size: Mordor Intelligence. Mordor Intelligence Market Research Company. (n.d.). https://www.mordorintelligence.com/industry-reports/acute-respiratory-distress-syndrome-treatment-market Paroxysmal nocturnal hemoglobinuria treatment market 2030. Paroxysmal Nocturnal Hemoglobinuria Treatment Market 2030. (n.d.). https://www.grandviewresearch.com/industry-analysis/paroxysmal-nocturnal-hemoglobinuria-pnh-market Trauma Care Centers Market Size & Share Report, 2022-2030. (n.d.). https://www.grandviewresearch.com/industry-analysis/trauma-care-centers-market

---

Why Now Next-Generation Precision Antibody Drug Conjugates (ADC) Candidates for the Treatment of Cancer​ Innovative Bi-Functional ADC Platform Technology Customizable Targets by Tumor, Novel Payloads, Unique Linkers to Generate a Pipeline of Superior ADCs for Out-Licensing Opportunities AKTX-101 (TROP2 PH1 ADC) Next-Generation Precision Bi-Functional ADC With Novel Spliceosome Inhibiting Payload Designed to Overcome Limitations of Current ADCs Significant Deal-Flow for Early-Stage ADC Continued Recent Momentum of ADC Deals Underscores Big Pharma Growing Interest and Engagement for Potential Deal Ongoing Robust BD Effort to Secure Licensing/Strategic Partner for AKTX-101 and Potential for Upside From Licensing of Non-Core Assets Capital Efficient Strategy Focused on Execution

---

Investor Relations JTC Team [e-mail] [phone] Next-Generation Precision Bi-Functional Antibody Drug Conjugates

Cover	Jan. 13, 2025
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 13, 2025
Entity File Number	001-36288
Entity Registrant Name	Akari Therapeutics, Plc
Entity Central Index Key	0001541157
Entity Tax Identification Number	98-1034922
Entity Incorporation, State or Country Code	X0
Entity Address, Address Line One	22 Boston Wharf Road FL 7
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	929
Local Phone Number	274-7510
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
ADR [Member]
Document Information [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing 2,000 Ordinary Shares
Trading Symbol	AKTX
Security Exchange Name	NASDAQ
Ordinary Shares, par value $0.0001 per share [Member]
Document Information [Line Items]
Title of 12(b) Security	Ordinary Shares, par value $0.0001 per share*
No Trading Symbol Flag	true

---